FDA Hears Concerns About The Unregulated CBD Market

  • Forbes | by: Holly Lawrence |
  • 06/04/2019 12:00 AM
A Call for Regulatory Oversight

The FDA hearing’s first speaker, Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, set the theme. “The absence to date, of advanced regulatory thinking relative to CBD has resulted in a maelstrom of false claims and shoddy quality standards,” Pitts said.

He called out “aggressive and misleading marketing campaigns” for CBD products, and urged, “It’s time for the proponents of CBD, including many highly vocal patients, physicians, pharmacists, manufacturers and distributors, to become part of the solution.

“Quality must always trump corporate convenience,” Pitts said, expressing the need for production quality oversight.

He also described a lack of a dosing schedule for CBD products. “When people are told to use CBD by physicians, pharmacists, friends or internet experts, they are not given any peer-reviewed guidelines on how they should take it or in what amounts — something that should never happen,” Pitts said.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Coronavirus: America’s drug supply needs a refill

Coronavirus: America’s drug supply needs a refill

The coronavirus outbreak that originated in China could put the health of millions of Americans at risk — but not in the ...  Read more

Are we close to a coronavirus medical breakthrough?

Are we close to a coronavirus medical breakthrough?

Center For Medicine Public Interest Peter Pitts joins Trace Gallagher to give his insight into coronavirus treatments. ...  Read more

Coronavirus sweeping across the U.S.

Coronavirus sweeping across the U.S.

Peter Pitts joins National Report to discuss social distancing...  Read more

DRUGWONKS BLOG